almagate has been researched along with Angiogenesis, Pathologic in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (72.22) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, H; Nakamura, S | 1 |
| Andrade, N; Araújo E Silva, PM; Crispim Ribeiro, J; de Moraes, MO; Fechine, FV; Savio, D | 1 |
| Raczyńska, D; Raczyńska, K; Zorena, K | 1 |
| Hong, J; Li, Y; Xu, J | 1 |
| Avitabile, T; Bonfiglio, V; Casuccio, A; Cennamo, G; Cillino, S; Furino, C; Longo, A; Pani, L; Parisi, G; Parravano, M; Reibaldi, M; Russo, A; Uva, MG; Xoxi, E | 1 |
| Donati, G; Mendrinos, E; Pournaras, CJ | 1 |
| Barakat, MR; Kaiser, PK | 1 |
| Funatsu, H | 1 |
| Claes, A; Hovinga, KE; Leenders, WP; Musters, GD; Peter Vandertop, W; Richel, DJ; Stalpers, LJ; van Furth, WR; Verhoeff, JJ | 1 |
| Adamis, AP; Ng, EW | 1 |
| Doggrell, SA | 1 |
| Canny, MD; De Erkenez, A; Jucker, F; Krilleke, D; Lee, JH; Ng, YS; Pardi, A; Shima, DT | 1 |
| Adamis, AP; Calias, P; Cunningham, ET; Guyer, DR; Ng, EW; Shima, DT | 1 |
| Ducharme, JF; Filippopoulos, T; Krzystolik, MG; Loewenstein, JI | 1 |
| Michels, S; Rosenfeld, PJ; Schmidt-Erfurth, U | 1 |
| Cavalli, M; Gatto, B | 1 |
| Bienias, W; Nowak, JZ | 1 |
| Joussen, AM | 1 |
11 review(s) available for almagate and Angiogenesis, Pathologic
| Article | Year |
|---|---|
[Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Diabetic Retinopathy; Drug Development; Humans; Macular Degeneration; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retina; Retinal Vein Occlusion; Vascular Endothelial Growth Factor A | 2021 |
Biomarkers in diabetic retinopathy and the therapeutic implications.
Topics: Adalimumab; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Aptamers, Nucleotide; Bevacizumab; Biomarkers; Diabetic Retinopathy; Etanercept; Eye Proteins; Humans; Immunoglobulin G; Infliximab; Interleukin-12; Mice; Neovascularization, Pathologic; Nerve Growth Factors; Quality of Life; Ranibizumab; Receptors, Tumor Necrosis Factor; Rituximab; Serpins; Somatomedins; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2013 |
Progress of anti-vascular endothelial growth factor therapy for ocular neovascular disease: benefits and challenges.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Eye; Humans; Neovascularization, Pathologic; Ranibizumab; Vascular Endothelial Growth Factor A | 2014 |
VEGF inhibitors for the treatment of neovascular age-related macular degeneration.
Topics: Animals; Aptamers, Nucleotide; Humans; Macular Degeneration; Neovascularization, Pathologic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
[Progress in therapy for and diagnosis of diabetic complications--diabetic retinopathies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Drug Design; Humans; Neovascularization, Pathologic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2009 |
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Macular Degeneration; Neovascularization, Pathologic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.
Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Humans; Macular Degeneration; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2005 |
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Clinical Trials as Topic; Diabetic Retinopathy; Drug Delivery Systems; Eye; Eye Diseases; Humans; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2006 |
Promising new treatments for neovascular age-related macular degeneration.
Topics: Aging; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Capillary Permeability; Cholestanols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Double-Blind Method; Drug Design; Drugs, Investigational; Eye Proteins; Humans; Injections; Lactates; Macular Degeneration; Models, Animal; Multicenter Studies as Topic; Neovascularization, Pathologic; Nerve Growth Factors; Pigment Epithelium of Eye; Protein Isoforms; Randomized Controlled Trials as Topic; RNA Interference; RNA, Small Interfering; Serpins; Stilbenes; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vitreous Body | 2006 |
[Age-related macular degeneration (AMD): etiopathogenesis and therapeutic strategies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antioxidants; Aptamers, Nucleotide; Bevacizumab; Humans; Lipofuscin; Macular Degeneration; Neovascularization, Pathologic; Photochemotherapy; Pregnadienediols; Ranibizumab; Retinal Drusen; Triamcinolone Acetonide | 2007 |
[Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Angiopathies; Diabetic Retinopathy; Humans; Infant, Newborn; Macular Degeneration; Neovascularization, Pathologic; Ranibizumab; Retinal Diseases; Retinopathy of Prematurity; Vascular Diseases | 2007 |
7 other study(ies) available for almagate and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Effect of Topical Instillation of Pegaptanib Sodium Upon Inflammatory Corneal Neovascularization in Rabbits.
Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Aptamers, Nucleotide; Caustics; Cornea; Corneal Injuries; Corneal Neovascularization; Disease Models, Animal; Inflammation; Instillation, Drug; Male; Neovascularization, Pathologic; Prednisolone; Rabbits; Sodium Hydroxide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2021 |
Association of neovascular age-related macular degeneration with month and season of birth in Italy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Female; Humans; Incidence; Italy; Macular Degeneration; Male; Neovascularization, Pathologic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Registries; Seasons; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib.
Topics: Adult; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Humans; Neovascularization, Pathologic; Optic Disk; Remission Induction; Severity of Illness Index; Vascular Endothelial Growth Factor A | 2009 |
Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma.
Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Disease-Free Survival; Female; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.
Topics: Aptamers, Nucleotide; Binding Sites; Binding, Competitive; Cells, Cultured; Dimerization; Endothelium, Vascular; Heparin; Humans; Macular Degeneration; Magnetic Resonance Spectroscopy; Models, Molecular; Neovascularization, Pathologic; Pichia; Polyethylene Glycols; Protein Binding; Protein Conformation; Protein Isoforms; Protein Structure, Secondary; Protein Structure, Tertiary; Pyrimidines; RNA; Signal Transduction; Thermodynamics; Vascular Endothelial Growth Factor A | 2005 |
Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy.
Topics: Aptamers, Nucleotide; Chemotherapy, Adjuvant; Diabetic Retinopathy; Glaucoma Drainage Implants; Glaucoma, Neovascular; Gonioscopy; Humans; Injections; Iris; Lens Implantation, Intraocular; Male; Middle Aged; Neovascularization, Pathologic; Phacoemulsification; Postoperative Complications; Vitrectomy | 2006 |
From proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Controlled Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Protein Engineering; Ranibizumab; RNA, Small Interfering; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2006 |